One test is enough: Japan's two-test rule for HIV treatment subsidies delays antiretroviral therapy without changing eligibility
- 1Chiba University Hospital
Abstract
IntroductionJapan achieves high retention and viral suppression among people on antiretroviral therapy, yet treatment starts late. Most people obtain subsidised treatment through a physical disability certificate for HIV-related immune dysfunction, which requires two blood tests at least four weeks apart. We quantified the diagnosis-to-treatment cascade, identified who waits and tested whether the second test changes certification.
MethodsRetrospective cohort of people newly diagnosed with HIV at 11 designated AIDS core hospitals in 2015 to 2024. We measured intervals from screening to hospital visit and to antiretroviral therapy, and emulated certification from the first test alone and from the two-test rule under every possible number of non-laboratory criteria (k = 0 to 8).
ResultsOf 1302 people (96% men; 68% with CD4 <350 cells/{micro}L or AIDS), 1036 (80%) followed the two-test pathway and 261 started treatment after one test, mostly because of AIDS or acute infection. People reached the hospital a median of 11 days after screening. Treatment then began a median of 70 days after the first visit in the two-test pathway and 11 days in the single-test pathway; 0.2% and 60.9% started within 14 days. Delay rose with CD4 count: 46 days when the mean count was [≤]200 cells/{micro}L, 117 days when it was >500 with a laboratory criterion (16% of the two-test pathway) and 334 days when it was >500 without one (3%; adjusted hazard ratio 0.14, 95% confidence interval 0.09 to 0.23). Medians ranged from 35 to 96 days across facilities. The second test changed little: the first CD4 count agreed with the mean of two (intraclass correlation coefficient 0.959), HIV-RNA [≥]5000 copies/mL persisted in 97.6%, and certification status agreed in 99.0% for k [≥]1 (92.5% for k = 0), with discordance concentrated near 500 cells/{micro}L; the first test gave a milder grade in at most 2.9%.
ConclusionsThe statutory second test adds at least four weeks before antiretroviral therapy in Japan without changing who is certified, and delays most the people with the highest CD4 counts. Certification on a single test, with treatment separated from the subsidy procedure, would remove a delay that has no clinical or administrative justification.
Related
- High Initiation but Suboptimal Completion of Tuberculosis-Preventive Treatment Among People Living With HIV on Antiretroviral Therapy, Persistent Tuberculosis Incidence, and Programmatic Implications: Findings From a 2-Year Multicountry Cohort Study
- Long-Acting Injectable Antiretroviral Therapy as a Catalyst for Engagement in Opioid Use Disorder Treatment Among People With HIV Who Use Drugs
- Temporal proximity to counseling is associated with longitudinal bedaquiline and antiretroviral therapy adherence in multidrug-resistant tuberculosis and HIV treatment
- Empiric tuberculosis treatment and 12-month mortality among sputum GeneXpert-negative adults living with HIV in Uganda in the era of widespread antiretroviral therapy: A prospective cohort study
- Risk factors for low-level viremia and virological failure in HIV patients in southwestern China who transitioned to second-line antiretroviral therapy after failure of first-line treatment: a retrospective cohort study
BibTeX
@misc{taniguchi2026test,
title = {{One test is enough: Japan's two-test rule for HIV treatment subsidies delays antiretroviral therapy without changing eligibility}},
author = {T. Taniguchi and T. Muramatsu and R. Minami and H. Nakamura and E. Adachi and R. Sekiya and K. Fukushima and J. Imamura and Y. Yoshino and M. Shirano and Y. Hirai and M. Imahashi},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.28.26364228},
url = {https://www.medrxiv.org/content/10.64898/2026.09.28.26364228v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - One test is enough: Japan's two-test rule for HIV treatment subsidies delays antiretroviral therapy without changing eligibility
AU - T. Taniguchi
AU - T. Muramatsu
AU - R. Minami
AU - H. Nakamura
AU - E. Adachi
AU - R. Sekiya
AU - K. Fukushima
AU - J. Imamura
AU - Y. Yoshino
AU - M. Shirano
AU - Y. Hirai
AU - M. Imahashi
PY - 2026
DA - 2026/09/28
PB - medRxiv
DO - 10.64898/2026.09.28.26364228
UR - https://www.medrxiv.org/content/10.64898/2026.09.28.26364228v1
AB - IntroductionJapan achieves high retention and viral suppression among people on antiretroviral therapy, yet treatment starts late. Most people obtain subsidised treatment through a physical disability certificate for HIV-related immune dysfunction, which requires two blood tests at least four weeks apart. We quantified the diagnosis-to-treatment cascade, identified who waits and tested whether the second test changes certification. MethodsRetrospective cohort of people newly diagnosed with HIV at 11 designated AIDS core hospitals in 2015 to 2024. We measured intervals from screening to hospital visit and to antiretroviral therapy, and emulated certification from the first test alone and from the two-test rule under every possible number of non-laboratory criteria (k = 0 to 8). ResultsOf 1302 people (96% men; 68% with CD4 <350 cells/{micro}L or AIDS), 1036 (80%) followed the two-test pathway and 261 started treatment after one test, mostly because of AIDS or acute infection. People reached the hospital a median of 11 days after screening. Treatment then began a median of 70 days after the first visit in the two-test pathway and 11 days in the single-test pathway; 0.2% and 60.9% started within 14 days. Delay rose with CD4 count: 46 days when the mean count was [≤]200 cells/{micro}L, 117 days when it was >500 with a laboratory criterion (16% of the two-test pathway) and 334 days when it was >500 without one (3%; adjusted hazard ratio 0.14, 95% confidence interval 0.09 to 0.23). Medians ranged from 35 to 96 days across facilities. The second test changed little: the first CD4 count agreed with the mean of two (intraclass correlation coefficient 0.959), HIV-RNA [≥]5000 copies/mL persisted in 97.6%, and certification status agreed in 99.0% for k [≥]1 (92.5% for k = 0), with discordance concentrated near 500 cells/{micro}L; the first test gave a milder grade in at most 2.9%. ConclusionsThe statutory second test adds at least four weeks before antiretroviral therapy in Japan without changing who is certified, and delays most the people with the highest CD4 counts. Certification on a single test, with treatment separated from the subsidy procedure, would remove a delay that has no clinical or administrative justification.
ER -